HK1070887A1 - Tricyclic thrombin receptor antagonists - Google Patents

Tricyclic thrombin receptor antagonists

Info

Publication number
HK1070887A1
HK1070887A1 HK05103479A HK05103479A HK1070887A1 HK 1070887 A1 HK1070887 A1 HK 1070887A1 HK 05103479 A HK05103479 A HK 05103479A HK 05103479 A HK05103479 A HK 05103479A HK 1070887 A1 HK1070887 A1 HK 1070887A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
thrombin receptor
tricyclic thrombin
tricyclic
antagonists
Prior art date
Application number
HK05103479A
Other languages
English (en)
Inventor
Chacklamannil Samuel
Clasby Martin
Greenlee William
Wang Yuguang
Xia Yan
Veltri Enrico
Chelliah Mariappan
Wu Wenxue
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1070887(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1070887A1 publication Critical patent/HK1070887A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05103479A 2002-04-16 2005-04-22 Tricyclic thrombin receptor antagonists HK1070887A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (1)

Publication Number Publication Date
HK1070887A1 true HK1070887A1 (en) 2005-06-30

Family

ID=29250954

Family Applications (3)

Application Number Title Priority Date Filing Date
HK05103479A HK1070887A1 (en) 2002-04-16 2005-04-22 Tricyclic thrombin receptor antagonists
HK09102736.6A HK1123302A1 (en) 2002-04-16 2009-03-23 Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
HK09108388.4A HK1129893A1 (en) 2002-04-16 2009-09-14 Tricyclic thrombin receptor antagonist

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK09102736.6A HK1123302A1 (en) 2002-04-16 2009-03-23 Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them
HK09108388.4A HK1129893A1 (en) 2002-04-16 2009-09-14 Tricyclic thrombin receptor antagonist

Country Status (34)

Country Link
US (3) US7304078B2 (no)
EP (5) EP1495018B3 (no)
JP (2) JP4558331B2 (no)
KR (1) KR101026929B1 (no)
CN (1) CN1659162B (no)
AR (1) AR039570A1 (no)
AT (3) ATE455774T1 (no)
AU (1) AU2003221932B2 (no)
BR (1) BRPI0309309B8 (no)
CA (1) CA2482858C (no)
CY (3) CY1107184T1 (no)
DE (3) DE60335679D1 (no)
DK (2) DK1495018T3 (no)
EC (1) ECSP045368A (no)
ES (3) ES2357876T3 (no)
FR (1) FR15C0047I2 (no)
HK (3) HK1070887A1 (no)
IL (1) IL164585A (no)
LT (1) LTC1495018I2 (no)
LU (1) LU92759I2 (no)
MX (1) MXPA04010308A (no)
MY (1) MY144040A (no)
NL (1) NL300746I2 (no)
NO (2) NO330500B1 (no)
NZ (2) NZ535880A (no)
PE (1) PE20040412A1 (no)
PL (1) PL214718B1 (no)
PT (2) PT2065384E (no)
RU (2) RU2329264C9 (no)
SG (1) SG164279A1 (no)
SI (2) SI2065384T1 (no)
TW (1) TWI343919B (no)
WO (1) WO2003089428A1 (no)
ZA (1) ZA200408342B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
JP4558788B2 (ja) * 2004-05-28 2010-10-06 シェーリング コーポレイション トロンビンレセプターアンタゴニストとしての条件付きヒンバシンアナログ
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US20060172397A1 (en) * 2005-01-14 2006-08-03 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
EP1853592B1 (en) * 2005-01-14 2011-03-02 Schering Corporation Synthesis of himbacine analogs
ES2374379T3 (es) * 2005-01-14 2012-02-16 Schering Corporation Síntesis exo y diastereoselectiva de análogos de himbacina.
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
MX2007008622A (es) * 2005-01-14 2007-09-11 Schering Corp Una sintesis exo-selectiva de analogos de himbacina.
AU2006230292A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
EP1971336A2 (en) * 2005-12-22 2008-09-24 Shering Corporation Thrombin receptor antagonists as phophylaxis to complications from cardiopulmonary surgery
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
AU2007238756A1 (en) 2006-04-13 2007-10-25 Schering Corporation Fused ring thrombin receptor antagonists
US8022088B2 (en) * 2006-06-29 2011-09-20 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AU2007305269A1 (en) 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
AR063095A1 (es) * 2006-10-04 2008-12-30 Schering Corp Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
CA2673228A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
CN101981034B (zh) 2008-02-05 2013-08-14 赛诺菲-安万特 作为par1抑制剂的三唑并哒嗪、其制备及其制备药物的用途
CA2713551C (en) 2008-02-05 2016-06-14 Sanofi-Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
WO2009143039A2 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
US8575351B2 (en) * 2009-06-04 2013-11-05 Merck Sharp & Dohme Corp. Active metabolite of a thrombin receptor antagonist
JP2012529431A (ja) 2009-06-08 2012-11-22 メルク・シャープ・アンド・ドーム・コーポレーション トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
PL2558465T3 (pl) 2010-04-16 2015-05-29 Sanofi Sa Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
EP2822557B1 (en) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
EP3035929B1 (en) * 2013-08-22 2024-07-03 Merck Sharp & Dohme LLC 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
WO2015026685A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017181993A1 (zh) * 2016-04-22 2017-10-26 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
WO2022018156A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
EP1036072B1 (en) * 1997-11-25 2004-05-06 Schering Corporation Thrombin receptor antagonists
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
PE20020235A1 (es) * 2000-06-15 2002-04-02 Schering Corp Derivados de nor-seco himbacina como antagonistas de los receptores de trombina
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
HUP0500443A3 (en) * 2001-10-18 2009-12-28 Schering Corp Himbacine analogues as thrombin receptor antagonists and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
US20070270439A1 (en) 2007-11-22
EP2065384B1 (en) 2011-01-05
AR039570A1 (es) 2005-02-23
PT2065384E (pt) 2011-03-16
EP1982984A2 (en) 2008-10-22
US7713999B2 (en) 2010-05-11
ES2297150T3 (es) 2008-05-01
CY1111363T1 (el) 2015-08-05
DE60331114D1 (de) 2010-03-11
US20030216437A1 (en) 2003-11-20
CN1659162A (zh) 2005-08-24
KR101026929B1 (ko) 2011-04-04
ATE378330T1 (de) 2007-11-15
DE60335679D1 (de) 2011-02-17
ES2297150T7 (es) 2012-03-16
NO20044963L (no) 2004-11-15
SG164279A1 (en) 2010-09-29
FR15C0047I1 (no) 2015-08-28
ATE455774T1 (de) 2010-02-15
RU2329264C2 (ru) 2008-07-20
SI2065384T1 (sl) 2011-05-31
EP1982984A3 (en) 2008-10-29
MY144040A (en) 2011-07-29
DK2065384T3 (da) 2011-05-02
DE60317493T2 (de) 2008-09-18
AU2003221932A1 (en) 2003-11-03
ZA200408342B (en) 2006-05-31
PT1495018E (pt) 2008-02-19
LU92759I2 (en) 2015-08-31
WO2003089428A1 (en) 2003-10-30
EP1982984B1 (en) 2013-02-13
PE20040412A1 (es) 2004-07-12
EP2065384A1 (en) 2009-06-03
CY2015029I1 (el) 2016-04-13
AU2003221932B2 (en) 2007-11-22
HK1129893A1 (en) 2009-12-11
EP1495018B3 (en) 2011-03-16
IL164585A (en) 2010-11-30
PL373332A1 (en) 2005-08-22
EP1495018B1 (en) 2007-11-14
NO2015016I2 (no) 2015-07-09
US7304078B2 (en) 2007-12-04
ATE494284T1 (de) 2011-01-15
ES2338171T3 (es) 2010-05-04
JP4558331B2 (ja) 2010-10-06
DK1495018T3 (da) 2008-02-18
CN1659162B (zh) 2011-08-31
CA2482858C (en) 2010-11-30
PL214718B1 (pl) 2013-09-30
EP1495018A1 (en) 2005-01-12
DE60317493T3 (de) 2018-07-12
NO2015016I1 (no) 2015-07-20
CA2482858A1 (en) 2003-10-30
SI1495018T1 (sl) 2008-04-30
ES2357876T3 (es) 2011-05-03
CY2015029I2 (el) 2016-04-13
NZ575139A (en) 2010-08-27
BRPI0309309B8 (pt) 2021-05-25
RU2008106401A (ru) 2009-08-27
NL300746I1 (no) 2016-01-21
CY1107184T1 (el) 2012-10-24
HK1123302A1 (en) 2009-06-12
US20070179187A1 (en) 2007-08-02
BRPI0309309B1 (pt) 2018-09-04
TWI343919B (en) 2011-06-21
NZ535880A (en) 2007-11-30
EP2062890A1 (en) 2009-05-27
NL300746I2 (no) 2016-01-21
JP2010132710A (ja) 2010-06-17
FR15C0047I2 (fr) 2016-05-06
EP1860106A1 (en) 2007-11-28
DE60317493D1 (en) 2011-01-13
MXPA04010308A (es) 2005-02-03
KR20040099441A (ko) 2004-11-26
RU2329264C9 (ru) 2009-04-20
ECSP045368A (es) 2005-01-03
LTC1495018I2 (lt) 2017-04-10
TW200404068A (en) 2004-03-16
JP2005528406A (ja) 2005-09-22
EP1860106B1 (en) 2010-01-20
BR0309309A (pt) 2005-02-15
NO330500B1 (no) 2011-05-02
EP2062890B1 (en) 2011-01-05
IL164585A0 (en) 2005-12-18
RU2004133375A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
HK1070887A1 (en) Tricyclic thrombin receptor antagonists
IL174538A0 (en) Thrombin receptor antagonists
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
HK1090922A1 (en) Cgrp receptor antagonists cgrp
IL153308A0 (en) Thrombin receptor antagonists
ZA200702790B (en) Thrombin receptor antagonists
IL165841A0 (en) Mchir antagonists
EP1641781A4 (en) BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
PL378753A1 (pl) Antagoniści receptora CCR-3
AU2003291959A8 (en) Novel glucagon antagonists
IL165727A0 (en) Chemokine antagonists
IL164016A0 (en) Azetidine derivatives as ccr-3 receptor antagonists
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
AU2003297773A8 (en) Heteroaryl peptidomimetics as thrombin receptor antagonists
EP1696949A4 (en) VEGF Receptor Antagonists
AU2003287219A8 (en) Il-8 receptor antagonists
IL162534A0 (en) Novel alkansulfonamides as endotheline antagonists
GB0302094D0 (en) EP4 receptor antagonists
GB0026327D0 (en) Thrombin receptor antagonists
SI1534736T1 (sl) Antagonisti Nogo receptorja
SI1294714T1 (sl) Antagonisti trobinskega receptorja
GB0317346D0 (en) 5-ht2b receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200414